RecruitingNCT07141862

Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method

Fertility Preservation in Children With Neuroblastoma or Ewing's Sarcoma: Detection of Residual Disease by a Sensitive Method


Sponsor

University Hospital, Clermont-Ferrand

Enrollment

89 participants

Start Date

Feb 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

In prepubertal patients, cryopreservation of ovarian or testicular tissue is currently the only available method for fertility preservation prior to gonadotoxic cancer treatments. However, this approach carries the risk of reintroducing malignant cells upon autotransplantation, particularly in cases of metastatic cancers such as neuroblastoma and Ewing sarcoma. Therefore, it is crucial to employ highly sensitive techniques to detect minimal residual disease (MRD) in preserved gonadal tissues. This study aims to identify the most effective detection method by comparing the sensitivity and specificity of reverse transcription quantitative PCR (RT-qPCR) and droplet digital PCR (ddPCR) in identifying MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues from patients treated for these malignancies during infancy.


Eligibility

Min Age: 2 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether ovarian or testicular tissue removed from children with certain cancers (neuroblastoma or Ewing sarcoma) contains residual cancer cells. The goal is to determine whether it is safe to use this tissue for future fertility restoration procedures. **You may be eligible if...** - You are a woman of any age diagnosed with a benign ovarian cyst requiring laparoscopy, OR - You are a man of any age diagnosed with non-obstructive infertility (azoospermia), OR - You are a prepubertal boy or girl diagnosed with neuroblastoma or Ewing sarcoma in infancy - You or your parent/guardian can provide written informed consent **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTRT-qPCR

Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using RT-qPCR

DIAGNOSTIC_TESTddPCR

Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using ddPCR


Locations(1)

University hospital

Clermont-Ferrand, Auvergne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07141862


Related Trials